Literature DB >> 2879982

Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2.

K Kawa-Ha, E Franco, S Doi, K Yumura, S Ishihara, A Tawa, H Yabuuchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2879982     DOI： 10.1016/s0140-6736(87)91980-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Authors:  Jeffrey I Cohen; Elaine S Jaffe; Janet K Dale; Stefania Pittaluga; Helen E Heslop; Cliona M Rooney; Stephen Gottschalk; Catherine M Bollard; V Koneti Rao; Adriana Marques; Peter D Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S Wayne; Richard F Little; Mitchell S Cairo; Nader K El-Mallawany; Daniel Fowler; Claude Sportes; Michael R Bishop; Wyndham Wilson; Stephen E Straus
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

2.  CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA.

Authors:  K Kawa-Ha; S Ishihara; T Ninomiya; K Yumura-Yagi; J Hara; F Murayama; A Tawa; K Hirai
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 3.  Severe chronic active Epstein-Barr virus infection syndrome.

Authors:  M Okano; S Matsumoto; T Osato; Y Sakiyama; G M Thiele; D T Purtilo
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

4.  Budd-Chiari syndrome and Epstein-Barr virus (EBV) associated plasmacytoma in a patient with chronic active EBV infection.

Authors:  S Nagafuchi; H Ishibashi; K Anzai; K Ohshima; Y Ohno; N Fukushima; M Hashizume; K Sugimachi; H Chuman; M Kikuchi
Journal:  Clin Investig       Date:  1994-11

5.  Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection.

Authors:  Masao Hagihara; Takahide Tsuchiya; Osamu Hyodo; Yoko Ueda; Kei Tazume; Aya Masui; Ayako Kanemura; Fumiaki Yoshiba; Shinji Takashimizu; Shohei Matzusaki; Shunichi Kato; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

6.  Optimal treatment for chronic active Epstein-Barr virus disease.

Authors:  Jeffrey I Cohen
Journal:  Pediatr Transplant       Date:  2009-06

7.  Clonal T-cell lymphoproliferation containing Epstein-Barr (EB) virus DNA in a patient with chronic active EB virus infection.

Authors:  S Ishihara; A Tawa; K Yumura-Yagi; M Murata; J Hara; H Yabuuchi; K Hirai; K Kawa-Ha
Journal:  Jpn J Cancer Res       Date:  1989-02

Review 8.  Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders.

Authors:  Akihisa Sawada; Masami Inoue
Journal:  Front Pediatr       Date:  2018-11-06       Impact factor: 3.418

9.  Severe degenerative change of multiple organs mediated by chronic active Epstein-Barr virus infection with infected T-cell expansion.

Authors:  Michihide Tokuhira; Atsushi Iizuka; Reiko Watanabe; Naoya Sekiguchi; Norihide Sato; Chen-Kang Chien; Yasunobu Sekiguchi; Tomoe Nemoto; Kyoko Hanzawa; Jun-Ichi Tamaru; Shinji Itoyama; Hiroshi Suzuki; Tsutomu Takeuchi; Shigehisa Mori; Masahiro Kizaki
Journal:  Int J Hematol       Date:  2008-04-23       Impact factor: 2.319

10.  A case of severe chronic active Epstein-Barr virus infection with T-cell lymphoproliferative disorder.

Authors:  Hyun Seok Cho; In Soon Kim; Hwan Cheol Park; Myung Ju Ahn; Young Yiul Lee; Chan Kum Park
Journal:  Korean J Intern Med       Date:  2004-06       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.